Edition:
United States

Qiagen NV (QIA.DE)

QIA.DE on Xetra

27.18EUR
14 Dec 2017
Change (% chg)

€-0.25 (-0.91%)
Prev Close
€27.43
Open
€27.19
Day's High
€27.33
Day's Low
€27.07
Volume
487,536
Avg. Vol
514,703
52-wk High
€31.52
52-wk Low
€25.41

Chart for

About

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and... (more)

Overall

Beta: 0.64
Market Cap(Mil.): €6,308.92
Shares Outstanding(Mil.): 230.83
Dividend: 1.01
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 196.13 16.04
EPS (TTM): -- -- --
ROI: -- -11.69 35.70
ROE: -- -36.44 15.40

Qiagen to pay Oxford Immunotec $27.5 million to settle patent case

Qiagen NV said on Friday it had agreed to pay $27.5 million to resolve a lawsuit claiming that a tuberculosis blood test it produces infringes patents held by competitor Oxford Immunotec Global PLC.

Dec 15 2017

BRIEF-Oxford Immunotec And Qiagen Reached A Settlement In Lawsuit

* OXFORD IMMUNOTEC GLOBAL - CO, QIAGEN REACHED A SETTLEMENT IN LAWSUIT IN U.S. COURT ALLEGING PATENT INFRINGEMENT IN RELATION TO QIAGEN'S PRODUCTS

Dec 15 2017

BRIEF-Qiagen To Transfer U.S. Listing Of Global Shares To Nyse

* QIAGEN TO TRANSFER U.S. LISTING OF GLOBAL SHARES TO NYSE Source text for Eikon: Further company coverage:

Dec 08 2017

As Brexit looms, UK pitches new industry plan, wins support from Merck, Qiagen

LONDON Britain pitched a new strategy for industry on Monday, pledging greater state intervention to tackle weak productivity and to help the world's sixth largest economy cope with the upheaval of leaving the European Union.

Nov 27 2017

As Brexit looms, UK pitches new industry plan, wins support from Merck, Qiagen

LONDON Britain pitched a new strategy for industry on Monday, pledging greater state intervention to tackle weak productivity and to help the world's sixth largest economy cope with the upheaval of leaving the European Union.

Nov 27 2017

UPDATE 2-As Brexit looms, UK pitches new industry plan, wins support from Merck, Qiagen

* Drug industry remains concerned about Brexit impact (Adds Prime Minister, Business Secretary comments, reaction)

Nov 27 2017

BRIEF-Qiagen NV posts qtrly adjusted EPS $0.32‍​

* Qiagen NV - reaffirming 2017 adjusted EPS target of $1.25-1.27 cer before restructuring‍​

Nov 06 2017

BRIEF-Qiagen, Centogene to collaborate in bioinformatics for genetic diseases

* Qiagen and Centogene to collaborate in bioinformatics for genetic diseases

Oct 09 2017

BRIEF-Angle partners Qiagen in liquid biopsy portolio

* Partnership will seek to combine angle's parsortix system for harvesting circulating tumor cells with qiagen's liquid biopsy solution portfolio Source text for Eikon: Further company coverage: (Reporting By London Bureau)

Sep 11 2017

BRIEF-Bookrunner says Qiagen transaction priced at 30 pct premium on upsized $400 mln issue size

* BOOKRUNNER SAYS TRANSACTION WILL PRICE AT 0.50% COUPON AND 30% PREMIUM ON AN UPSIZED $400M ISSUE SIZE

Sep 06 2017

Earnings vs. Estimates